23ME-01473

· 23andMe, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 23ME-01473, covering 2024-12-04 to 2024-12-04. Get the full timeline:

Most recent: Clinical Trial Update: Study of 23ME-01473 in Patients With Advanced Solid Malignancies [Phase 1, Phase 2]